Core Viewpoint - The Chinese synthetic biology manufacturing industry is experiencing rapid growth, with projections indicating a market size approaching 800 billion yuan in 2024 and nearly 1 trillion yuan in 2025, reflecting a growth rate of 26.2% from 2024. The industry is expected to exceed 1 trillion yuan by 2026 and reach 1,703.7 billion yuan by 2027, driven by policy incentives and technological breakthroughs [2]. Industry Overview - The primary focus of the Chinese synthetic biology manufacturing sector is on biopharmaceutical products, which are projected to reach a market size of 334.3 billion yuan in 2024, accounting for 42.9% of the total industry. The demand for biopharmaceuticals is expected to increase due to the ongoing development of new therapies such as cell and gene therapies [3]. Regional Distribution - The synthetic biology manufacturing industry in China exhibits a "three-legged" structure, with significant contributions from East China, North China, and Central South China. By the first half of 2025, these three regions are expected to collectively exceed 700 billion yuan, with East China leading at 311.5 billion yuan, supported by favorable policies and industrial collaboration [4]. Industry Chain Structure - The synthetic biology manufacturing industry chain consists of upstream raw material supply, midstream product processing, and downstream terminal sales applications. Upstream includes various biomass raw materials and biomanufacturing equipment. Midstream encompasses biopharmaceuticals, bio-foods, agricultural bio-products, bio-based materials, and biofuels. Downstream involves terminal sales and applications in healthcare, agriculture, environmental protection, and daily chemicals [7].